OnDose Study Demonstrates Need for Improved Dosing Approach for Colorectal Cancer Patients

Myriad Genetics MYGN announced today that a study published in Clinical Colorectal Cancer entitled "Body Surface Area-based Dosing of 5-Fluoruracil Results in Extensive Inter-individual Variability in 5-Fluroruracil Exposure in Colorectal Cancer Patients on FOLFOX Regimens" demonstrated Body Surface Area dosing in colorectal cancer patients receiving FOLFOX treatment regimens resulted in a wide range of drug plasma concentrations, with most patients falling well outside the target range. "These findings demonstrate the importance of providing physicians with a diagnostic that can help optimize dosing in FOLFOX therapy," stated Mark Capone, President of Myriad Genetic Laboratories, Inc. "Myriad's OnDose® product aids physicians in determining the most efficacious therapeutic dose for FOLFOX treatment for colorectal cancer patients, all while minimizing toxic side effects."